Daily Respiratory Research Analysis
Three impactful respiratory-related studies stood out today: a Nature paper mechanistically linking Epstein–Barr virus to multisystem inflammatory syndrome in children via TGF-β signaling; real-world evidence from Western Australia showing nirsevimab’s high effectiveness (≈88%) against RSV-associated pediatric hospitalizations; and a multicenter cohort from India revealing high rates of bedaquiline resistance with poor outcomes in MDR-TB, underscoring the need for routine BDQ drug-susceptibility
Summary
Three impactful respiratory-related studies stood out today: a Nature paper mechanistically linking Epstein–Barr virus to multisystem inflammatory syndrome in children via TGF-β signaling; real-world evidence from Western Australia showing nirsevimab’s high effectiveness (≈88%) against RSV-associated pediatric hospitalizations; and a multicenter cohort from India revealing high rates of bedaquiline resistance with poor outcomes in MDR-TB, underscoring the need for routine BDQ drug-susceptibility testing.
Research Themes
- Viral immunopathology and host–pathogen interactions in pediatric inflammatory syndromes
- Prevention of respiratory infections: monoclonal antibody effectiveness against RSV
- Antimicrobial resistance in pulmonary infections: bedaquiline resistance in MDR-TB
Selected Articles
1. TGFβ links EBV to multisystem inflammatory syndrome in children.
This multi-center mechanistic study identifies a link between Epstein–Barr virus (EBV) and multisystem inflammatory syndrome in children (MIS-C) mediated by TGF-β signaling. The work delineates immune pathways connecting prior viral exposures to post–SARS-CoV-2 hyperinflammation in pediatric patients, highlighting potential biomarkers and therapeutic targets.
Impact: By uncovering a mechanistic EBV–TGF-β axis in MIS-C, this study reframes pathogenesis and opens avenues for targeted interventions in severe pediatric inflammatory disease.
Clinical Implications: Enhanced screening for EBV reactivation and TGF-β–related immune signatures in suspected MIS-C could refine risk stratification. TGF-β pathway modulation and antiviral strategies targeting EBV may warrant investigation as adjunctive therapies.
Key Findings
- Identifies a mechanistic link between EBV and MIS-C mediated through TGF-β signaling.
- Maps immune pathways connecting prior viral exposure to post–SARS-CoV-2 hyperinflammation in children.
- Suggests candidate biomarkers and therapeutic targets along the TGF-β axis.
Methodological Strengths
- Multicenter, translational immunology approach integrating human pediatric samples.
- Mechanistic focus on signaling pathways increases biological plausibility.
Limitations
- Abstract does not provide sample size or detailed cohort characteristics.
- Causality and therapeutic efficacy require prospective interventional validation.
Future Directions: Prospective studies validating EBV/TGF-β biomarkers in MIS-C, and early-phase trials of TGF-β pathway modulation or EBV-targeted interventions in severe pediatric hyperinflammation.
In a subset of children and adolescents, SARS-CoV-2 infection induces a severe acute hyperinflammatory shock
2. Bedaquiline Resistance and Treatment Outcomes Among Patients With Tuberculosis Previously Exposed to Bedaquiline in India: A Multicentric Retrospective Cohort Study.
Among 117 bedaquiline-exposed TB patients, 36% harbored BDQ-resistant strains. BDQ resistance was associated with lung cavities and clofazimine resistance and strongly predicted unfavorable outcomes (87% unfavorable, 40% mortality). The authors recommend routine BDQ DST and rapid resistance testing to prevent treatment failure.
Impact: Emerging BDQ resistance threatens cornerstone MDR-TB regimens and shows high mortality. This multicenter cohort provides actionable evidence to implement routine BDQ susceptibility testing and guide regimen design.
Clinical Implications: In BDQ-exposed patients, implement baseline BDQ phenotypic (and where possible genotypic) DST, consider cross-resistance (e.g., clofazimine), and prioritize regimens with at least four effective drugs. Invest in rapid BDQ resistance assays and pharmacovigilance.
Key Findings
- 36% (42/117) of BDQ-exposed TB patients had bedaquiline-resistant strains.
- BDQ resistance correlated with lung cavities (RR 1.8) and clofazimine resistance (RR 2.3).
- Unfavorable outcomes occurred in 87% of BDQ-resistant patients, including 40% mortality and 40% treatment failure.
Methodological Strengths
- Multicenter cohort with standardized BDQ phenotypic DST.
- Clinically meaningful outcomes (mortality, failure) with risk estimates (RR, 95% CI).
Limitations
- Retrospective design may introduce selection and information bias.
- Limited sample size and regional scope may affect generalizability.
Future Directions: Prospective surveillance of BDQ resistance with integrated genotypic markers; development and field validation of rapid BDQ resistance assays; regimen optimization trials incorporating BDQ-DST to improve outcomes.
BACKGROUND: Bedaquiline (BDQ) resistance presents a critical challenge in the fight against tuberculosis (TB), particularly multidrug-resistant (MDR) strains. The emergence of resistance to BDQ, a key drug in treating MDR-TB, poses significant threats to TB treatment effectiveness. METHODS: The National Institute of Tuberculosis and Respiratory Diseases in Delhi and the Médecins Sans Frontières clinic in Mumbai provide BDQ, delamanid, and carbapenem-based regimens for patients with suspected or confirmed treatment failure. BDQ phenotypic drug-susceptibility testing (DST) was performed for all BDQ-exposed patients. Treatment regimens were individualized based on exposure history, comorbidities, drug interactions, prior adverse drug reactions, and DST results. RESULTS: Of 117 BDQ-exposed patients from December 2020-December 2022, 42 (36%) exhibited a BDQ-resistant strain. Median (IQR) age was 24 (22-32) years, with 63 (54%) females and 94% with pulmonary TB. Patients with a BDQ-resistant strain were older (median age: 27 vs 23 years; P = .04), more likely to have lung cavities (risk ratio [RR]: 1.8; 95%-CI: 1.1-3.1; P = .02), and be resistant to clofazimine (RR: 2.3; 95%-CI: 1.5-3.6; P = .001). Overall, 102 patients initiated treatment. Patients with BDQ-resistance had higher risk of unfavorable outcomes compared with BDQ-susceptible patients (RR:2.1; 95%-CI: 1.5-2.8; P < .001). Overall, 87% (33/38) of patients with BDQ-resistance experienced unfavorable treatment outcomes: 15 (40%) died, 15 (40%) had treatment failure, and 3 (8%) were lost-to-follow-up. CONCLUSIONS: The study highlights a concerning rate of BDQ-resistance among previously treated patients, resulting in poor treatment outcomes. To prevent treatment failure, we recommend implementing BDQ-DST, developing affordable and accurate rapid tests for BDQ-resistance, and intensifying research and development efforts for newer TB drugs.
3. Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024.
In a test-negative, hospital-based study across three WA hospitals, nirsevimab showed 88.2% adjusted effectiveness against RSV-associated hospitalization over one epidemic season (n=284). Despite breakthrough infections, disease severity did not differ between immunized and unimmunized children.
Impact: Provides timely real-world effectiveness evidence for statewide RSV prevention in infants and high-risk toddlers, informing immunization policy and program scale-up.
Clinical Implications: Supports implementation of seasonal nirsevimab for infants and high-risk second-season children. Monitoring breakthrough infections and optimizing program coverage are key to maximize population impact.
Key Findings
- Adjusted effectiveness of nirsevimab against RSV-associated hospitalization was 88.2% (95% CI 73.5–94.7) over April–October 2024.
- Among 284 children, 22.8% of immunized children had RSV infection, but illness severity did not differ by immunization status.
- Program coverage differed between cases (22.8%) and controls (60.0%), consistent with strong protective effect.
Methodological Strengths
- Test-negative design reduces healthcare-seeking and testing biases for vaccine/antibody effectiveness.
- Hospital-based laboratory confirmation of RSV and standardized data collection across sites.
Limitations
- Single-season observation with moderate sample size limits precision for subgroups.
- Non-randomized design cannot fully exclude residual confounding (e.g., differential healthcare access).
Future Directions: Multi-season effectiveness and safety surveillance, cost-effectiveness analyses, and evaluation of co-administration strategies with routine immunizations to optimize coverage.
BACKGROUND: Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season. This study describes the effectiveness of nirsevimab against RSV hospitalisation over a single epidemic season. METHODS: Between April and October 2024, children hospitalised with laboratory-confirmed RSV-associated acute respiratory infection (ARI) and test-negative controls were enrolled from three hospitals in WA. Demographic variables, medical risk factors, symptoms and outcomes were assessed. Nirsevimab effectiveness in preventing RSV-associated hospitalisation was estimated. RESULTS: Over 7 months, 284 children eligible for nirsevimab were enrolled including 184 RSV positive cases and 100 controls. Coverage of nirsevimab in RSV cases was 22.8% and 60.0% in controls. The overall adjusted effectiveness of nirsevimab against RSV-associated ARI hospitalisation was 88.2% (95% CI: 73.5, 94.7). RSV infection occurred in 42 (22.8%) children who had received nirsevimab; there was no significant difference in RSV illness severity among those immunised and unimmunised. CONCLUSION: Nirsevimab was highly effective at preventing RSV-associated ARI hospitalisation in young children in the southern hemisphere. SUMMARY: This study is the first Australian study to provide nirsevimab effectiveness estimate against RSV hospitalisation over a single epidemic season. The adjusted estimate of nirsevimab effectiveness against RSV-associated ARI hospitalisation was 88.2%, similar to those reported from Northern Hemisphere countries.